SCN10A
Sodium channel protein type 10 subunit alpha
As of the edition of 20 October 2026, SCN10A (sodium channel protein type 10 subunit alpha, UniProt Q9Y5Y9) has 62 drugs tested at it and 14 companies on the list, 1 on route A and 6 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9Y5Y9
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 8
- Disease areas
- Nervous system; Mental health; Injuries; Cancer; Bones, joints and muscles; Heart and blood vessels; Nutrition and metabolism; Urinary and reproductive
- Registered trials of its drugs
- 2,746
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 46 |
| Active | 4 |
| Went quiet | 7 |
| Stopped | 1 |
| Withdrawn from market | 1 |
| Status not established | 3 |
| Total | 62 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Lidocaine | Marketed | Phase 4 | none listed |
| Ropivacaine | Marketed | Phase 4 | none listed |
| Topiramate | Marketed | Phase 4 | none listed |
| Lamotrigine | Marketed | Phase 4 | none listed |
| Carbamazepine | Marketed | Phase 4 | none listed |
| Lacosamide | Marketed | Phase 4 | Ended 2026 |
| Riluzole | Marketed | Phase 4 | none listed |
| Tetracaine | Marketed | Phase 4 | none listed |
| Eslicarbazepine acetate | Marketed | Phase 4 | Ended 2026 |
| Zonisamide | Marketed | Phase 4 | none listed |
| Phenytoin | Marketed | Phase 4 | none listed |
| Articaine | Marketed | Phase 4 | none listed |
12 of 62 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 6 |
| Engaged | 6 |
| Undetermined | 1 |
| Total on the list | 14 |
The other 11 companies at SCN10A
In the product14 companies in all; 11 are not named here, and no score is.
See the 14 companies at SCN10A, ranked, with the facts behind eachRequest access. Nothing is shown until you do.